Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Harmony Biosciences Management, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
8 min read
Harmony Biosciences Management, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Harmony Biosciences Management, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r
Read →
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals a
Read →
Hangzhou Yirui Pharmaceutical Technology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hangzhou Yirui Pharmaceutical Technology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Yirui Pharmaceutical Technology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals
Read →
Hangzhou Shangjian Biotechnology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hangzhou Shangjian Biotechnology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Shangjian Biotechnology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outr
Read →
Hangzhou QIANYUAN Pollen Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
8 min read
Hangzhou QIANYUAN Pollen Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou QIANYUAN Pollen Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals a
Read →
Hangzhou Highlightll Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hangzhou Highlightll Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Highlightll Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and o
Read →
Hangzhou Chengbang Pharmaceutical Technology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hangzhou Chengbang Pharmaceutical Technology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Chengbang Pharmaceutical Technology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial sign
Read →
Hangzhou Bangshun Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
8 min read
Hangzhou Bangshun Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Bangshun Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outr
Read →
Hangzhou Atom Therapeutics Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hangzhou Atom Therapeutics Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hangzhou Atom Therapeutics Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r
Read →
Halia Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Halia Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Halia Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →
Hainan Dermavon Pharmaceutical Technology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Hainan Dermavon Pharmaceutical Technology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Hainan Dermavon Pharmaceutical Technology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals
Read →
Haihe Biopharma Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
Latest Hotspot
9 min read
Haihe Biopharma Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Haihe Biopharma Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Read →